Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise

Executive Summary

Pfizer's acquisition of King Pharmaceuticals will be the Big Pharma's first "bolt-on" purchase since its mega acquisition of Wyeth in 2009 and fits neatly into a strategy it articulated to a jittery Wall Street for months ("Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?" "The Pink Sheet," Jan. 26, 2009.
Advertisement

Related Content

Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Sandoz Pushes Further Into High-Barrier Generics With $1.5B Acquisition of Fougera
Nycomed US Crowns New Management; Plans New Direction
King Pharma's Second Quarter Disappoints; Looks to Pain Approvals and Diversification
Pfizer's Focus Is On "Bolt-On" Acquisitions After Wyeth Merger
No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials
Now Who Needs a Painkiller? King and Pain Therapeutics Face a Remoxy Setback
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
Can an Overthrown King Help Mylan?

Topics

Advertisement
UsernamePublicRestriction

Register

PS052732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel